Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record now presents details for the completed ALPHA phase II study of afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma, including its eligibility criteria, treatment plan, outcomes, and publication.SummaryDifference44%

- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces updates to NIH terminology, including a transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record page now displays a 403 Forbidden error page, with the site header and footer visible, indicating restricted access to the content.SummaryDifference18%

Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.